Article After Article After Article.....says the same thing ....and why, with the completion of testing, significant financing this week (ignore the sp for a few days), preliminary manufacturing agreements established and a final FDA submission, that AcuVid could very well find itself leading the pack.
"
The emergence of the omicron varianthas also posed new challenges to the accuracy of RATs. According to Chunhuei Chi, director of the Center for Global Health at Oregon State University in the United States, some recent studies suggest that because the omicron variant may be concentrated more around patients' throats or mouths in the beginning, when they try to take samples from their noses using RATs, the sensitivity of the tests may be lower."
Have a great weekend!!!